EntryPoint Capital’s RAPT Therapeutics RAPT Stock Holding History

EntryPoint Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,238	Closed	-$161K	–	1482
2024 Q1	$161K	Buy	+2,238	New	+$311K	0.14%	188

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

EntryPoint Capital's RAPT Position: Q2 2024 in Review

EntryPoint Capital sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 2,238 shares — an estimated $161K sold.

EntryPoint Capital first reported a position in RAPT in Q1 2024 and held it in 1 quarter. The position peaked at $161K in Q1 2024. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

EntryPoint Capital reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 2,238 RAPT Therapeutics shares in Q2 2024, an estimated $161K.
EntryPoint Capital first reported a position in RAPT Therapeutics in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's RAPT Therapeutics position peaked at $161K in Q1 2024.
103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.